Sinecura

Sinecura Therapeutics is a biotechnology company focused on developing novel cancer therapies by targeting the hypoxic tumor microenvironment. A spin-out from the University of Oxford, the company builds upon the pioneering research of Nobel laureate Sir Peter Ratcliffe regarding how cells sense and adapt to oxygen availability. Sinecura utilizes a proprietary discovery platform to identify and validate therapeutic targets that are essential for tumor survival under low-oxygen conditions. Their primary focus is the development of small molecule inhibitors designed to disrupt these survival mechanisms in solid tumors. The company is backed by prominent investors such as Oxford Science Enterprises and aims to address the resistance of hypoxic tumors to standard treatments.